Improving the managed entry of new medicines: Sharing experiences across Europe

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 12, Issue 4, 2012, Pages 439-441

  Godman, Brian ^a,b,c   Paterson, Ken ^d   Malmström, Rickard E ^a   Selke, Gisbert ^e   Fagot, Jean Paul ^f   Mrak, Jana ^g  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^d Scottish Medicines Consortium   (United Kingdom)

^e Wissenschaftliches Institut der AOK WIdO   (Germany)

^f Direction de la Stratégie des Etudes et des Statistiques DSES   (France)

^g Health Insurance Institute of Slovenia   (Slovenia)

Author keywords

demand side measures; horizon scanning; HTA; indicators; managed entry; pharmaceuticals

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANXIOLYTIC AGENT; BENFLUOREX; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPNOTIC AGENT; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PIOGLITAZONE; PLACEBO; PROTON PUMP INHIBITOR; PSYCHOTROPIC AGENT; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG CONTROL; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG USE; EUROPE; HEART ATRIUM FIBRILLATION; HUMAN; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRESCRIPTION; RISK MANAGEMENT;

DRUG COSTS; EUROPE; HEALTH EXPENDITURES; HUMANS; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS;

EID: 84866651651     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.12.44     Document Type: Conference Paper

References (14)

1. Godman B, Shrank W, Andersen M et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilisation: changes seen and global implications. Expert Rev. Pharmacoecon. Outcomes Res. 10, 707-722 (2010
2. Garattini S, Bertele V, Godman B et al. Enhancing the rational use of new medicines across European healthcare systems - a position paper. Eur. J. Clin. Pharmacol. 64, 1137-1138 (2008
3. Kaiser J. New cystic fibrosis drug offers hope, at a price. Science 335, 645 (2012
4. Wettermark B, Godman B, Eriksson C et al. [Introduction of new medicines into European healthcare systems]. GGW 10(3), 24-34 (2010
5. Godman B, Bucsics A, Burkhardt T et al. Insight into recent reforms and initiatives in Austria; implications for key stakeholders. Expert Rev. Pharmacoecon. Outcomes Res. 8, 357-371 (2008
6. Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, Reynier JP. Ongoing pharmaceutical reforms in France; implications for key stakeholder groups. Appl. Health Econ. Health Policy 8, 7-24 (2010
7. Wettermark B, Persson M, Wilking N et al. Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Services Res. 10, 128 (2010
8. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N. Engl. J. Med. 366, 864-866 (2012
9. Mannuci M, Nobil A, Garattini S. New drugs for thromboprophylaxis in atrial fibrillation. Eur. J. Int. Med. 23, 1-5 (2012
10. Malmstrom RE. New anticoagulants. In: Essential Guide to Blood Coagulation. Antovic JP, Blomback M (Eds). Wiley-Blackwell Publishing, Oxford, UK, 91-102 (2009
11. Joppi R, Dematte L, Menti AM, Pase D, Poggiani C, Mezzalira L; Italian Horizon Scanning Project Group. The Italian Horizon Scanning Project. Eur. J. Clin. Pharmacol. 65(8), 775-781 (2009
12. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B Evidence B(i)ased Medicine -selective Reporting from Studies Sponsored by Pharmaceutical Industry: Review of Studies in New Drug Applications. BMJ 326, 1171 (2003
13. Adamski J, Godman B, Ofierska-Sujkowska G et al. Review of risk sharing schemes for pharmaceuticals: considerations, critical evaluation and recommendations for European payers. BMC Health Servic. Res. 10, 153 (2010
14. Gustafsson LL, Wettermark B, Godman B et al. The 'Wise List' - a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin. Pharmacol. Toxicol. 108, 224-233 (2011